abstract
- The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- July 1999
has subject area
- 0304 Medicinal and Biomolecular Chemistry (FoR)
- 0305 Organic Chemistry (FoR)
- 1115 Pharmacology and Pharmaceutical Sciences (FoR)
- Administration, Oral (MeSH)
- Animals (MeSH)
- Biological Availability (MeSH)
- CHO Cells (MeSH)
- Cricetinae (MeSH)
- Cyclooxygenase 1 (MeSH)
- Cyclooxygenase 2 (MeSH)
- Cyclooxygenase 2 Inhibitors (MeSH)
- Cyclooxygenase Inhibitors (MeSH)
- Enzyme Inhibitors (MeSH)
- Humans (MeSH)
- Indomethacin (MeSH)
- Inhibitory Concentration 50 (MeSH)
- Isoenzymes (MeSH)
- Lactones (MeSH)
- Medicinal & Biomolecular Chemistry (Science Metrix)
- Membrane Proteins (MeSH)
- Prostaglandin-Endoperoxide Synthases (MeSH)
- Rats (MeSH)
- Sulfones (MeSH)